Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN HBC 7 IN PLASTIC CONTAINER versus CLINIMIX E 5 20 SULFITE FREE W ELECT IN 20 DEXTROSE W CALCIUM IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN HBC 7 IN PLASTIC CONTAINER versus CLINIMIX E 5 20 SULFITE FREE W ELECT IN 20 DEXTROSE W CALCIUM IN PLASTIC CONTAINER.
AMINOSYN-HBC 7% IN PLASTIC CONTAINER vs CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential and nonessential amino acids to support protein synthesis and nitrogen balance in patients with metabolic stress or hepatic encephalopathy.
Parenteral nutrition providing essential amino acids, electrolytes, and dextrose for caloric support and protein synthesis.
1-2 L/day intravenously (equivalent to 70-140 g amino acids/day) for adults; infuse at no more than 0.1 g/kg/h.
Intravenous. Adult: 2 L/day (providing 100 g protein and 400 g dextrose) or as per metabolic needs. Rate: 100 mL/hr initially, adjusted based on tolerance and glucose monitoring.
None Documented
None Documented
Terminal elimination half-life of infused amino acids is approximately 0.5-1 hour for free amino acids, but varies by individual amino acid. Clinical context: rapid clearance in critically ill patients due to increased metabolic demand.
Amino acids: 0.5-2 hours (rapid clearance dependent on metabolic demand). Glucose: ~2-4 hours in euglycemic states. No single terminal half-life due to mixture.
Renal: 100% of infused amino acids are metabolized or excreted renally as urea and other nitrogenous waste products. No biliary or fecal elimination.
Components are primarily metabolized; nitrogen waste excreted renally as urea (85-90%), with minimal biliary/fecal elimination (<5%). Electrolytes and dextrose are fully metabolized or excreted renally.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution